Bryostatin-1: Pharmacology and therapeutic potential as a CNS drug

96Citations
Citations of this article
105Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Bryostatin-1 is a powerful protein kinase C (PKC) agonist, activating PKC isozymes at nanomolar concentrations. Pharmacological studies of bryostatin-1 have mainly been focused on its action in preventing tumor growth. Emerging evidence suggests, however, that bryostatin-1 exhibits additional important pharmacological activities. In preclinical studies bryostatin-1 has been shown at appropriate doses to have cognitive restorative and antidepressant effects. The underlying pharmacological mechanisms may involve an activation of PKC isozymes, induction of synthesis of proteins required for long-term memory, restoration of stress-evoked inhibition of PKC activity, and reduction of neurotoxic amyloid accumulation and tau protein hyperphosphorylation. The therapeutic potential of bryostatin-1 as a CNS drug should be further explored. © 2006 The Authors.

Cite

CITATION STYLE

APA

Sun, M. K., & Alkon, D. L. (2006, March). Bryostatin-1: Pharmacology and therapeutic potential as a CNS drug. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2006.00001.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free